CA2222573A1 - Utilisation d'agents agonistes du recepteur adrenergique alpha-1c-selectif dans le traitement de l'incontinence urinaire - Google Patents

Utilisation d'agents agonistes du recepteur adrenergique alpha-1c-selectif dans le traitement de l'incontinence urinaire Download PDF

Info

Publication number
CA2222573A1
CA2222573A1 CA002222573A CA2222573A CA2222573A1 CA 2222573 A1 CA2222573 A1 CA 2222573A1 CA 002222573 A CA002222573 A CA 002222573A CA 2222573 A CA2222573 A CA 2222573A CA 2222573 A1 CA2222573 A1 CA 2222573A1
Authority
CA
Canada
Prior art keywords
alpha
human
adrenoceptor
activates
selective agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222573A
Other languages
English (en)
Inventor
Carlos C. Forray
Charles Gluchowski
Theresa A. Branchek
Douglas A. Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptic Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/459,410 external-priority patent/US5610174A/en
Application filed by Individual filed Critical Individual
Publication of CA2222573A1 publication Critical patent/CA2222573A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention se rapporte à un procédé pour traiter l'incontinence urinaire chez un sujet, procédé qui consiste à administrer à ce sujet une quantité thérapeutiquement efficace d'un agent agoniste .alpha.¿1C? sélectif qui active un récepteur .alpha.¿1C?-adrénergique humain au moins dix fois plus qu'il n'active un récepteur .alpha.¿1A? adrénergique humain et un récepteur .alpha.¿1B? adrénergique humain. Cette invention se rapporte en outre à un procédé pour provoquer une contraction de tissus de l'urètre et du col vesical, ce procédé consistant à mettre en contact ces tissus de l'urètre et du col vesical avec une quantité d'un agent agoniste .alpha.¿1C?-sélectif propre à produire une contraction, cet agent agoniste activant à un récepteur .alpha.¿1C?-adrénergique humain au moins dix fois plus qu'il n'active un récepteur .alpha.¿1A? adrénergique humain et un récepteur .alpha.¿1B? adrénergique humain. Cette invention se rapporte également à des composés pour traiter l'incontinence urinaire et pour servir à provoquer une contraction des tissus de l'urètre et du col vesical.
CA002222573A 1995-06-02 1996-05-30 Utilisation d'agents agonistes du recepteur adrenergique alpha-1c-selectif dans le traitement de l'incontinence urinaire Abandoned CA2222573A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45984695A 1995-06-02 1995-06-02
US08/459,410 1995-06-02
US08/459,410 US5610174A (en) 1995-06-02 1995-06-02 Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US08/459,846 1995-06-02

Publications (1)

Publication Number Publication Date
CA2222573A1 true CA2222573A1 (fr) 1996-12-05

Family

ID=27039338

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222573A Abandoned CA2222573A1 (fr) 1995-06-02 1996-05-30 Utilisation d'agents agonistes du recepteur adrenergique alpha-1c-selectif dans le traitement de l'incontinence urinaire

Country Status (5)

Country Link
EP (1) EP0835107A1 (fr)
JP (1) JPH11507024A (fr)
AU (1) AU6003596A (fr)
CA (1) CA2222573A1 (fr)
WO (1) WO1996038143A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US20020183357A1 (en) * 2000-02-17 2002-12-05 Brioni Jorge D. Use of alpha- 1- alpha adrenoceptor agonists with alpha-1-Beta antagonism for the treatment of stress urinary incontinence
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
DE10104369A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz
WO2015152196A1 (fr) * 2014-03-31 2015-10-08 東レ株式会社 Dérivé d'imidazoline et utilisation pharmaceutique dudit dérivé
CN105622434B (zh) * 2015-12-31 2018-03-13 天津英吉诺科技有限公司 1‑(2,5‑二甲氧基苯基)‑2‑氨基乙醇的制备方法

Also Published As

Publication number Publication date
WO1996038143A1 (fr) 1996-12-05
EP0835107A1 (fr) 1998-04-15
JPH11507024A (ja) 1999-06-22
AU6003596A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
US5610174A (en) Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US5403847A (en) Use of α1C specific compounds to treat benign prostatic hyperlasia
US5578611A (en) Use of α-1C specific compounds to treat benign prostatic hyperplasia
JP7463318B2 (ja) ６員アザヘテロ環を含有するデルタ－オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
TW200306837A (en) Adenosine A2a receptor antagonists
TW200530213A (en) Novel heterocycles as IGF-1R inhibitors
US6583140B2 (en) 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
JP2022547079A (ja) てんかんを治療する方法を使用しててんかんを治療する方法
US5508306A (en) Aromatic amine derivatives
WO1995007075A9 (fr) Nouveaux derives d'amine aromatique
CA2222573A1 (fr) Utilisation d'agents agonistes du recepteur adrenergique alpha-1c-selectif dans le traitement de l'incontinence urinaire
US7119103B2 (en) β3-Adrenoreceptor agonists, agonist compositions and methods of using
US6172066B1 (en) Dihydropyrimidines and uses thereof
US6706716B2 (en) Compounds specific for the human α1d adrenergic receptor and uses thereof
US6602888B2 (en) Use of α1C specific compounds to treat benign prostatic hyperplasia
Craig et al. Use of α1A‐selective adrenoceptor agonists for the treatment of urinary incontinence
US6046331A (en) Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
CA2687973C (fr) Composes d'((heteroaryle bicyclique) imidazolyle) methyle heteroaryle utilises en tant qu'agonistes des recepteurs adrenergiques
US20040106623A1 (en) Compounds specific for the human alpha1d adrenergic receptor and uses thereof
JP2000500470A (ja) ジヒドロピリミジンおよびその使用
FR2700541A1 (fr) Nouveaux composés de 1,4-dihydropyridine, leur procédé de préparation et les compositions pharmaceutiques les contenant.

Legal Events

Date Code Title Description
FZDE Dead